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Background
In patients with metastatic breast cancer that is positive for human epidermal 
growth factor receptor 2 (HER2), progression-free survival was significantly im-
proved after first-line therapy with pertuzumab, trastuzumab, and docetaxel, as 
compared with placebo, trastuzumab, and docetaxel. Overall survival was signifi-
cantly improved with pertuzumab in an interim analysis without the median being 
reached. We report final prespecified overall survival results with a median follow-
up of 50 months.
Methods
We randomly assigned patients with metastatic breast cancer who had not received 
previous chemotherapy or anti-HER2 therapy for their metastatic disease to receive 
the pertuzumab combination or the placebo combination. The secondary end 
points of overall survival, investigator-assessed progression-free survival, indepen-
dently assessed duration of response, and safety are reported. Sensitivity analyses 
were adjusted for patients who crossed over from placebo to pertuzumab after the 
interim analysis.
Results
The median overall survival was 56.5 months (95% confidence interval [CI], 49.3 to 
not reached) in the group receiving the pertuzumab combination, as compared with 
40.8 months (95% CI, 35.8 to 48.3) in the group receiving the placebo combination 
(hazard ratio favoring the pertuzumab group, 0.68; 95% CI, 0.56 to 0.84; P<0.001), 
a difference of 15.7 months. This analysis was not adjusted for crossover to the per-
tuzumab group and is therefore conservative. Results of sensitivity analyses after ad-
justment for crossover were consistent. Median progression-free survival as assessed 
by investigators improved by 6.3 months in the pertuzumab group (hazard ratio, 0.68; 
95% CI, 0.58 to 0.80). Pertuzumab extended the median duration of response by 
7.7 months, as independently assessed. Most adverse events occurred during the admin-
istration of docetaxel in the two groups, with long-term cardiac safety maintained.
Conclusions
In patients with HER2-positive metastatic breast cancer, the addition of per tuzumab 
to trastuzumab and docetaxel, as compared with the addition of placebo, signifi-
cantly improved the median overall survival to 56.5 months and extended the re-
sults of previous analyses showing the efficacy of this drug combination. (Funded 
by F. Hoffmann–La Roche and Genentech; CLEOPATRA ClinicalTrials.gov number, 
NCT00567190.)
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The overexpression of human epi-dermal growth factor receptor 2 (HER2) in breast cancer results in more aggressive 
disease with a poor prognosis.1 The humanized 
anti-HER2 monoclonal antibodies pertuzumab 
and trastuzumab are more active in combination 
than alone because of more comprehensive sig-
naling blockade.2,3 We investigated combination 
therapy with docetaxel for first-line treatment of 
HER2-positive metastatic breast cancer in the 
Clinical Evaluation of Pertuzumab and Tras-
tuzumab (CLEOPATRA) trial. Analysis of the pri-
mary end point showed that patients who re-
ceived pertuzumab, trastuzumab, and docetaxel 
(pertuzumab group) had a significantly longer 
median progression-free survival, as assessed by 
independent reviewers, than did those who re-
ceived placebo, trastuzumab, and docetaxel (con-
trol group) (hazard ratio favoring the pertuzu-
mab group, 0.62).4 The second interim analysis 
of overall survival confirmed significantly longer 
survival in the pertuzumab group (hazard ratio, 
0.66).5 Safety profiles (including cardiac) were 
similar and consistent across the two study 
groups and the analysis time points.4-6 Here we 
report follow-up data at a median of 50 months 
regarding overall survival, investigator-assessed 
progression-free survival and safety, and inde-
pendently assessed duration of response.
Me thods
Study Design and Patients
In this randomized, double-blind, placebo-con-
trolled, phase 3 trial,4,5 we enrolled patients who 
were at least 18 years of age with locally recur-
rent, unresectable, or metastatic HER2-positive 
breast cancer that was centrally confirmed. Eligi-
ble patients had a left ventricular ejection fraction 
(LVEF) of 50% or more at baseline, had an East-
ern Cooperative Oncology Group performance 
status of 0 or 1, and had received no more than 
one hormonal treatment for metastatic disease. 
Adjuvant or neoadjuvant chemotherapy with or 
without trastuzumab was allowed. Patients were 
excluded if they had central-nervous-system me-
tastases, if the LVEF was less than 50% during or 
after previous trastuzumab therapy, or if they 
had received other anticancer therapy (with the 
exception of one previous hormonal regimen) or 
had a cumulative exposure of more than 360 mg 
of doxorubicin per square meter of body-surface 
area or its equivalent. All randomization and 
masking processes and assessments have been 
reported previously.4,5
After significant improvement in overall 
survival was reported with pertuzumab (Perjeta, 
F. Hoffmann–La Roche and Genentech),5 pa-
tients who were still receiving the placebo com-
bination in whom disease had not progressed 
were invited to cross over to receive pertuzumab. 
Overall survival results presented here are from 
the intention-to-treat population; therefore, data 
from crossover patients were analyzed in the 
control group. Two sensitivity analyses of overall 
survival were conducted: one in which data from 
crossover patients were censored at the time of 
the first pertuzumab dose and one in which these 
patients were excluded from the results. Post-
crossover safety data are reported separately.
The CLEOPATRA trial was performed in ac-
cordance with Good Clinical Practice guidelines 
and the provisions of the Declaration of Helsinki. 
Protocol approval was obtained from an inde-
pendent ethics committee at each study site. All 
patients provided written informed consent.
Study Oversight
The study was designed by the senior academic 
authors and representatives of the sponsors, 
F. Hoffmann–La Roche and Genentech. Data 
were collected by the sponsors and analyzed in 
collaboration with the senior academic authors, 
who vouch for the completeness and accuracy of 
the data and analyses and for the fidelity of the 
study to the protocol. The protocol, including the 
statistical analysis plan, is available with the full 
text of this article at NEJM.org. All investigators 
participating in the study agreed to confidential-
ity regarding the data. The first author prepared 
the initial draft of the manuscript with assistance 
from a medical writer employed by Health Inter-
actions and funded by F. Hoffmann–La Roche. 
All authors contributed to subsequent drafts and 
made the decision to submit the manuscript for 
publication.
Study Procedures
Study drugs were administered intravenously 
every 3 weeks. Pertuzumab (at a dose of 840 mg) 
or placebo was given on day 1 of cycle 1, followed 
by 420 mg on day 1 of each subsequent cycle; 
trastuzumab (Herceptin, F. Hoffmann–La Roche 
and Genentech) at a dose of 8 mg per kilogram of 
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body weight was administered on day 2 of cycle 1, 
followed by 6 mg per kilogram on day 1 of the 
remaining cycles. Pertuzumab or placebo and 
trastuzumab were administered until disease pro-
gression or the occurrence of unmanageable 
toxic effects; dose reductions were not allowed. 
Docetaxel was given at a dose of 75 mg per 
square meter on day 2 of cycle 1 and on day 1 of 
the remaining cycles; at least six cycles were rec-
ommended, but fewer cycles were allowed in case 
of disease progression or unmanageable toxic ef-
fects, and more cycles were allowed at the discre-
tion of the investigator or patient. Docetaxel 
could be escalated to 100 mg per square meter if 
there were no unmanageable toxic effects and 
could be reduced by 25% in the case of myelosup-
pression, hepatic dysfunction, or other toxic ef-
fects. Growth-factor support could be added 
according to prescribing information and the 
guidelines of the American Society of Clinical 
Oncology.7 No concurrent hormonal therapy was 
allowed before disease progression.
Study End Points
Since independent review of progression-free sur-
vival and the objective response rate were stopped 
after the first analysis,4 we report updated data 
on the secondary end points of overall survival 
(time from randomization to death from any 
cause) and investigator-assessed progression-free 
survival, which was defined as the time from 
randomization to the first documented radio-
graphic evidence of progressive disease, accord-
ing to Response Evaluation Criteria in Solid Tu-
mors (RECIST), version 1.0,8 or death from any 
cause within 18 weeks after the last investigator 
assessment of tumors. We also present the dura-
tion of response from the time of the data cutoff 
for the primary analysis.
Statistical Analysis
Data for patients who were alive or lost to follow-
up were censored at the last date they were 
known to be alive or at the time of randomiza-
tion plus 1 day, if no information was available 
after baseline. For the final analysis of overall 
survival, we determined that the study would 
have a power of 80% to detect a 33% improve-
ment in the pertuzumab group (hazard ratio for 
death from any cause, 0.75) after the occurrence 
of 385 deaths. The statistical stopping boundary 
for each interim analysis was established with 
the use of the O’Brien–Fleming approach and 
was crossed at the second interim analysis; con-
sequently, this final analysis is considered to be 
descriptive.
We used the log-rank test to compare overall 
survival between the two treatment groups, with 
stratification according to status with respect to 
adjuvant or neoadjuvant chemotherapy and geo-
graphic region. Kaplan–Meier analyses were used 
to estimate medians. A Cox proportional-hazards 
model was used to estimate hazard ratios and 
95% confidence intervals with the same stratifi-
cation factors.
Subgroup analyses were performed to ensure 
robustness of the treatment effect across pre-
specified categories. All analyses were performed 
with the use of SAS software, version 8.2 (SAS 
Institute).
R esult s
Study Population
Patients were enrolled from February 12, 2008, 
through July 7, 2010. The cutoff for data collec-
tion for this analysis was February 11, 2014. (En-
rollment and randomization are shown in Fig. 1.) 
Baseline characteristics were similar in the two 
study groups; 630 patients (88.0%) had visceral 
disease.4,5 A total of 389 patients had died at the 
time of this analysis. Median follow-up was 49.5 
months (range, 0 to 70) in the pertuzumab group 
and 50.6 months (range, 0 to 69) in the control 
group. After the interim analysis of overall sur-
vival in May 2012, investigators were informed 
about study-group assignments. Between July 
and November 2012, a total of 48 of the 406 pa-
tients (11.8%) in the control group crossed over 
to receive pertuzumab.
Overall Survival
Intention-To-Treat Population
Deaths were reported in 168 of 402 patients 
(41.8%) in the pertuzumab group and in 221 of 
406 patients (54.4%) in the control group (haz-
ard ratio favoring the pertuzumab group, 0.68; 
95% confidence interval [CI], 0.56 to 0.84; 
P<0.001) (Fig. 2A). The median overall survival 
was 56.5 months (95% CI, 49.3 to not reached) in 
the pertuzumab group and 40.8 months (95% CI, 
35.8 to 48.3) in the control group, a difference of 
15.7 months. The estimated Kaplan–Meier over-
all survival rate was 94.4% (95% CI, 92.1 to 96.7) 
The New England Journal of Medicine 
Downloaded from nejm.org at TAMPERE UNIVERSITY LIBRARY on February 16, 2016. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
Pertuzumab Combination in HER2-Positive Breast Cancer
n engl j med 372;8 nejm.org february 19, 2015 727
in the pertuzumab group and 89.0% (95% CI, 
85.9 to 92.1) in the control group at 1 year; 80.5% 
(95% CI, 76.5 to 84.4) and 69.7% (95% CI, 65.0 to 
74.3), respectively, at 2 years; 68.2% (95% CI, 63.4 
to 72.9) and 54.3% (95% CI, 49.2 to 59.4), respec-
tively, at 3 years; and 57.6% (95% CI, 52.4 to 62.7) 
and 45.4% (95% CI, 40.2 to 50.6), respectively, at 
4 years. Exploratory analyses in predefined sub-
groups showed a consistent benefit with pertuz-
umab (Fig. 2B). The hazard ratio for death from 
any cause among patients who had previously 
been treated with trastuzumab (47 patients in 
the pertuzumab group and 41 patients in the 
control group) was 0.80 (95% CI, 0.44 to 1.47).
808 Were enrolled and underwent
randomization
1196 Patients were screened
388 Did not meet inclusion
criteria or declined to
participate
402 Were assigned to receive
pertuzumab, trastuzumab,
and docetaxel
406 Were assigned to receive
placebo, trastuzumab,
and docetaxel
402 Were included in the
intention-to-treat
population
67 Were alive and re-
ceiving randomized 
treatment
125 Were alive and in
survival follow-up
42 Withdrew consent or
were lost to follow-up
168 Died
406 Were included in the
intention-to-treat
population
358 Did not cross over to
pertuzumab group
6 Were alive and 
receiving random-
ized treatment
90 Were alive and in
survival follow-up
42 Withdrew consent
or were lost to
follow-up
220 Died
48 Crossed over to per-
tuzumab group
31 Were alive and re-
ceiving crossover
treatment
15 Were alive and in 
survival follow-up
1 Withdrew consent 
1 Died
2 Did not receive
any treatment
9 Received nonran-
domized treatment
1 Received nonran-
domized treatment
2 Did not receive
any treatment
338 Withdrew from study
treatment
41 Withdrew for safety
reasons
34 Had adverse events
7 Died
297 Withdrew for non-
safety reasons
264 Had progressive
disease
2 Had violation of
selection criteria
at entry
21 Declined treatment
4 Failed to return
6 Had other reasons
345 Withdrew from study
treatment
36 Withdrew for safety
reasons
23 Had adverse events
13 Died
309 Withdrew for non-
safety reasons
281 Had progressive
disease
1 Had violation of
selection criteria
at entry
1 Had other proto-
col violation
23 Declined treatment
1 Failed to return
2 Had other reasons
396 Were included in the
safety population
408 Were included in the
safety population
Figure 1. Enrollment and Outcomes.
All patients who underwent randomization were included in the intention-to-treat population, and patients who received at least one 
dose of a study drug were included in the safety analysis. Reasons for withdrawals are shown. Included in the safety population are nine 
patients in the control group who received pertuzumab and one patient in the pertuzumab group who received placebo, as indicated.
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Sensitivity Analyses
The 48 patients without disease progression who 
opted to cross over from the control group to 
receive pertuzumab had all been receiving treat-
ment for 2 years or longer. When their data were 
censored at the time of the first pertuzumab 
dose, the median overall survival was 56.5 
months (95% CI, 49.3 to not reached) in the per-
tuzumab group and 39.6 months (95% CI, 35.0 to 
45.1) in the control group (hazard ratio, 0.63; 
B Subgroup Analysis of Overall Survival
A Overall Survival
0.6 1.0 2.0 3.0 4.0
Placebo BetterPertuzumab Better
All patients
Previous adjuvant or 
neoadjuvant treatment
No
Yes
Region
Europe
North America
South America
Asia
Age
<65 yr
≥65 yr
Age
<75 yr
≥75 yr
Race or ethnic group
White
Black
Asian
Other
Disease type
Visceral
Nonvisceral
ER or PgR status
Positive
Negative
HER2 status 
IHC 3+
FISH-positive
No. of
Patients Hazard Ratio (95% CI)Subgroup
0.71 (0.53–0.96)
1.11 (0.66–1.85)
0.61 (0.47–0.81)
0.66 (0.53–0.81)
0.69 (0.56–0.85)
0.59 (0.48–0.74)
0.82 (0.58–1.17)
0.37 (0.13–1.06)
0.68 (0.55–0.83)
0.63 (0.49–0.82)
0.41 (0.11–1.45)
0.85 (0.26–2.73)
0.53 (0.31–0.90)
0.70 (0.56–0.87)
0.82 (0.57–1.16)
0.50 (0.30–0.85)
0.63 (0.37–1.07)
0.65 (0.47–0.91)
0.70 (0.53–0.93)
0.67 (0.55–0.82)
0.2 0.4
0.64 (0.48–0.85)
P Value for
Interaction
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789
19
480
30
261
37
630
178
388
408
721
767
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350
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289
268
230
40 50
226
179
104
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28
23
1
0
0
0
Pertuzumab, 168 events
Control, 221 events
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95% CI, 0.52 to 0.78; P<0.001) (Fig. S1A in the 
Supplementary Appendix, available at NEJM.org). 
When crossover patients were excluded, the me-
dian overall survival was 56.5 months (95% CI, 
49.3 to not reached) in the pertuzumab group 
and 34.7 months (95% CI, 31.2 to 39.4) in the 
control group (hazard ratio for death from any 
cause, 0.55; 95% CI, 0.45 to 0.67; P<0.001) (Fig. 
S1B in the Supplementary Appendix).
Investigator-Assessed Progression-Free 
Survival
In the investigator-assessed intention-to-treat 
analysis, events occurred in 284 of 402 patients 
(70.6%) in the pertuzumab group and 320 of 406 
patients (78.8%) in the control group (hazard ra-
tio, 0.68; 95% CI, 0.58 to 0.80; P<0.001) (Fig. 3A). 
The results of subgroup analyses were consistent 
(Fig. 3B). The medians were unchanged from the 
May 2012 interim analysis (18.7 months in the 
pertuzumab group and 12.4 months in the con-
trol group, an improvement of 6.3 months).5
Duration of Response
The duration of response was independently as-
sessed in patients with a confirmed partial or 
complete response at the time of the primary 
analysis (275 patients in the pertuzumab group 
and 233 in the control group). Median durations 
of response were 20.2 months in the pertuzumab 
group (95% CI, 16.0 to 24.0) and 12.5 months in 
the control group (95% CI, 10.0 to 15.0).
Breast-Cancer Therapies after 
Discontinuation of study treatment
Among the 704 patients in the intention-to-treat 
population who received breast-cancer therapies 
after the discontinuation of the study treatment, 
the proportions of patients who received various 
drugs was balanced in the two study groups (Ta-
ble 1). A total of 72.9% patients in the pertuz-
umab group and 71.5% in the control group re-
ceived HER2-targeted therapy.
Treatment Exposure
The median number of study-treatment cycles re-
ceived by patients in the safety population was 24 
in the pertuzumab group (range, 1 to 96; 197 
patients received more than the median number) 
and 15 in the control group (range, 1 to 67). Pa-
tients who crossed over to the pertuzumab group 
received a median of 22.5 cycles of pertuzumab 
(range, 1 to 28), which was similar to the median 
number of cycles received by patients in the per-
tuzumab safety population. Docetaxel exposure 
did not change between data cutoffs (median, 8 
cycles in each group).
Side-Effect Profile and Cardiac Safety
All Patients
Rates of adverse events remained consistent with 
those in the primary analysis, with headache, up-
per respiratory tract infection, and muscle spasm 
reported as new adverse events with a difference 
of at least 5 percentage points between groups. 
Most events were grade 1 or 2 and occurred dur-
ing docetaxel administration and declined after 
discontinuation. A list of the most common ad-
verse events of all grades that occurred at a fre-
quency of 25% or more or showed a difference of 
at least 5 percentage points between study groups 
overall is provided in Table S1 in the Supplemen-
tary Appendix. Table 2 shows the rates of the 
same most common adverse events after the dis-
continuation of docetaxel.
The rate of left ventricular dysfunction, as 
defined by the National Cancer Institute Com-
mon Terminology Criteria for Adverse Events, 
version 3.0, and the New York Heart Associa-
tion,6 was somewhat lower in the pertuzumab 
group than in the control group (6.6% [27 of 408 
patients] vs. 8.6% [34 of 396 patients]). There 
Figure 2 (facing page). Overall Survival.
Panel A shows Kaplan–Meier estimates of overall sur-
vival in the intention-to-treat population, stratified ac-
cording to adjuvant or neoadjuvant therapy and geo-
graphic region. The median overall survival among 
patients receiving pertuzumab, trastuzumab, and doce-
taxel (pertuzumab group) was 56.5 months, 15.7 months 
longer than survival among patients receiving placebo, 
trastuzumab, and docetaxel (control group). The tick 
marks indicate censoring events. Panel B shows hazard 
ratios and 95% confidence intervals for overall survival 
in all prespecified subgroups according to baseline 
characteristics, without stratification. Race or ethnic 
group was determined by the investigator. “Other” in-
cludes American Indian or Alaska Native, Native Ha-
waiian or other Pacific Islander, and other populations. 
A grade of 3+ on immunohistochemical (IHC) analysis 
indicates positivity for human epidermal growth factor 
receptor 2 (HER2). For the assessment of HER2 status, 
prespecified subgroup analyses were restricted to pa-
tients whose tumors had an IHC score of 3+ or fluores-
cence in situ hybridization (FISH) positive status, since 
these categories accounted for approximately 90% of 
patients. CI denotes confidence interval, ER estrogen 
receptor, and PgR progesterone receptor.
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was one new event of symptomatic left ventricu-
lar dysfunction in the pertuzumab group after 
40 months, an event that resolved after 3 months 
with both antibodies discontinued. Reductions 
in the LVEF of 10% or more from baseline to an 
absolute value of less than 50% occurred in 24 of 
B Subgroup Analysis of Progression-free Survival
A Progression-free Survival
0.6 1.0 2.0
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neoadjuvant treatment
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Disease type
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ER or PgR status
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Negative
HER2 status
IHC 3+ 
FISH-positive
No. of
Patients Hazard Ratio (95% CI)Subgroup
0.73 (0.58–0.91)
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0.64 (0.51–0.81)
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0.77 (0.58–1.03)
0.45 (0.20–1.01)
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0.54 (0.19–1.51)
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394 patients (6.1%) in the pertuzumab group 
and 28 of 378 patients (7.4%) in the control 
group. Declines were reversed in 21 of 24 pa-
tients (87.5%) in the pertuzumab group and 22 
of 28 patients (78.6%) in the control group.
Most deaths were due to disease progression 
(in 150 of 408 patients [36.8%] in the per-
tuzumab group and 196 of 396 patients [49.5%] 
in the control group). Other causes of death 
were febrile neutropenia or infection (in 7 of 408 
patients [1.7%] in the pertuzumab group and 6 
of 396 patients [1.5%] in the control group) and 
causes that were classified as “other” or “un-
known” (in 12 of 408 patients [2.9%] in the 
pertuzumab group and 15 of 396 patients [3.8%] 
in the control group).
Crossover Population
No new safety signals were identified among pa-
tients in the control group who crossed over to 
receive pertuzumab. Most events were of grade 1 
or 2. Of the 221 events in the crossover group, 
7 were grade 3 events, and 2 were grade 4 events 
(diarrhea and dehydration in the same patient). 
There was one death from an unknown cause. 
No symptomatic left ventricular dysfunction was 
reported after crossover. Two patients had as-
ymptomatic reductions in the LVEF.
Discussion
First-line therapy with pertuzumab, trastuzumab, 
and docetaxel significantly improved overall sur-
vival among patients with HER2-positive meta-
static breast cancer, as compared with placebo, 
trastuzumab, and docetaxel. Since this was an 
intention-to-treat analysis, patients in the control 
group who crossed over to receive pertuzumab 
were included in the control group, a factor that 
added to the strength of the findings. The be-
tween-group separation in the Kaplan–Meier 
curves occurred early and was maintained over 
time. Findings in subgroup analyses were consis-
tent with the final results and the results of pre-
vious analyses.
We were able to estimate the treatment effect 
on the basis of a median overall survival of 56.5 
months in the pertuzumab group, a duration 
that is exceptionally long in this population of 
patients. In previous prospective studies of first-
line therapy with trastuzumab plus chemother-
apy in patients with HER2-positive metastatic 
breast cancer, the median overall survival has 
ranged from 25.1 months to 38.1 months.9-13 The 
progression-free survival benefit was also main-
tained over time in our study.4,5
The majority of adverse events occurred dur-
ing docetaxel treatment. Long-term cardiac safe-
ty was maintained, since treatment with pertuz-
umab did not increase cardiac toxicity (including 
asymptomatic and symptomatic left ventricular 
dysfunction), as compared with placebo. Symp-
toms developed at a later time with pertuzumab 
and quality of life did not differ from that in the 
control group during the chemotherapy period 
in the pertuzumab group.14
Table 1. Breast-Cancer Treatments Received by Patients Who Discontinued 
Study Treatment.*
Treatment
Control Group
(N = 369)
Pertuzumab 
Group  
(N = 335)
no. of patients (%)
Any treatment received after discon-
tinuing study treatment
291 (78.9) 258 (77.0)
HER2-targeted treatment 208 (71.5) 188 (72.9)
Trastuzumab 121 (41.6) 117 (45.3)
Pertuzumab 4 (1.4) 2 (0.8)
Lapatinib 142 (48.8) 124 (48.1)
Trastuzumab emtansine 34 (11.7) 32 (12.4)
Capecitabine 170 (58.4) 142 (55.0)
Vinorelbine 88 (30.2) 67 (26.0)
Doxorubicin 56 (19.2) 41 (15.9)
Cyclophosphamide 49 (16.8) 41 (15.9)
Taxanes 56 (19.2) 39 (15.1)
Hormonal treatments 56 (19.2) 69 (26.7)
* Percentages are based on the numbers of patients in the intention-to-treat pop-
ulation who received any treatment after the discontinuation of study drugs. 
Patients who discontinued treatment include 4 patients who were not treated 
and 17 patients who crossed over to  receive pertuzumab and subsequently 
withdrew from crossover treatment.
Figure 3 (facing page). Progression-free Survival.
Panel A shows Kaplan–Meier estimates of investigator-
assessed progression-free survival in the intention-to-
treat population, stratified according to adjuvant or 
neoadjuvant therapy and geographic region. The medi-
an progression-free survival was 18.7 months in the 
pertuzumab group as compared with 12.4 months in 
the control group, an improvement of 6.3 months. The 
tick marks indicate censoring events. Panel B shows 
hazard ratios and 95% confidence intervals for investi-
gator-assessed progression-free survival in all prespeci-
fied subgroups according to baseline characteristics, 
without stratification.
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Preclinical data showed that combining per-
tuzumab and trastuzumab resulted in greater ac-
tivity than that with either antibody alone owing 
to more comprehensive signaling blockade, since 
the antibodies bind to different HER2 epitopes.2,3 
The BO17929 study initially showed that the 
combination of pertuzumab plus trastuzumab 
was active in patients with advanced breast 
cancer following progression15 and subsequently 
showed that it was the combination, rather than 
pertuzumab alone, that was responsible for the 
activity.16 The efficacy of combination therapy 
was also shown among patients receiving neo-
adjuvant therapy, with the use of pertuzumab, 
trastuzumab, and docetaxel resulting in higher 
rates of complete response on pathological 
analysis, as compared with trastuzumab plus 
docetaxel, pertuzumab plus docetaxel, or pertuz-
umab plus trastuzumab.17 These data supported 
the use of neoadjuvant pertuzumab with trastuz-
umab and docetaxel in patients with HER2-
positive breast cancer, an indication that was 
recently approved by the Food and Drug Admin-
istration.18
Despite the clinically meaningful survival re-
sults in our study, important questions remain 
to be addressed in this field. First, most deaths 
in the study were due to breast cancer; therefore, 
better treatments are still needed. This is particu-
larly important in patients with early disease, 
such as those in the ongoing Adjuvant Pertuzu-
mab and Herceptin in Initial Therapy of Breast 
Cancer (APHINITY) trial (ClinicalTrials.gov num-
ber, NCT01358877). Second, it is not clear 
whether hormonal therapy plus pertuzumab and 
trastuzumab is more effective than hormonal 
therapy plus trastuzumab alone in patients with 
hormone receptor–positive disease. Third, there 
is no biomarker in addition to HER2 that pre-
dicts which patients with HER2-positive disease 
would benefit most from the combination of 
pertuzumab and trastuzumab.19-21 The presence 
of mutated PIK3CA may indicate an adverse prog-
nosis for patients with metastatic disease but 
did not have a predictive value in our study.21 
Whether other chemotherapeutic agents could 
improve on the safety profile is a fourth area for 
investigation. A phase 2 study assessing progres-
sion-free survival at 6 months with pertuzumab, 
trastuzumab, and paclitaxel showed few grade 3 
or 4 adverse events and no cardiac events.22 Fi-
nally, the question of when, if ever, therapy with 
pertuzumab plus trastuzumab for metastatic 
breast cancer should be stopped remains unan-
swered. With trastuzumab, continuing therapy 
after progression and adding a different chemo-
therapeutic agent resulted in prolonged progres-
sion-free survival,23 and lapatinib added to tras-
tuzumab was superior to lapatinib monotherapy 
with respect to progression-free and overall sur-
vival.24 The current recommendation is to dis-
continue pertuzumab after progression, but clini-
cal trials are warranted to determine the most 
effective duration of therapy.
This analysis has several limitations. First, 
patients who crossed over to receive pertuz u-
mab were included in the control group, which 
Table 2. Adverse Events after the Discontinuation of Docetaxel in the Safety 
Population.*
Adverse Event
Control Group  
(N = 261)
Pertuzumab Group  
(N = 306)
Most common events of any grade 
— no. of patients (%)†
Alopecia 6 (2.3) 5 (1.6)
Diarrhea‡ 37 (14.2) 86 (28.1)
Neutropenia 13 (5.0) 10 (3.3)
Nausea 30 (11.5) 39 (12.7)
Fatigue 25 (9.6) 41 (13.4)
Rash‡ 21 (8.0) 56 (18.3)
Asthenia 23 (8.8) 41 (13.4)
Decreased appetite 14 (5.4) 22 (7.2)
Peripheral edema 32 (12.3) 28 (9.2)
Vomiting 17 (6.5) 30 (9.8)
Myalgia 19 (7.3) 25 (8.2)
Mucosal inflammation 4 (1.5) 11 (3.6)
Headache 32 (12.3) 52 (17.0)
Constipation 18 (6.9) 17 (5.6)
Upper respiratory tract infection‡ 32 (12.3) 56 (18.3)
Pruritus‡ 15 (5.7) 42 (13.7)
Febrile neutropenia 0 0
Dry skin 10 (3.8) 10 (3.3)
Muscle spasm‡ 6 (2.3) 24 (7.8)
* Data are for patients who received at least one dose of a study drug after com-
pleting docetaxel treatment. Data for overall adverse events are provided in 
Table S1 in the Supplementary Appendix.
† The most common events are those that occurred with a frequency of 25% or 
more overall (including during the docetaxel treatment period) or that differed 
by 5 percentage points or more in frequency between the two groups overall.
‡ The frequency of this event was at least 5 percentage points greater in the 
pertuzumab group, as compared with the control group.
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in the intention-to-treat analysis favored the 
control group. Even so, the treatment effect fa-
vored pertuzumab in sensitivity analyses that 
excluded the crossover group (hazard ratio, 0.55) 
and that censored data at the time of the first 
pertuzumab dose (hazard ratio, 0.63), since data 
for patients with a good therapeutic response, 
who had continued to receive study treatment 
for a long time, were censored or excluded from 
the control group but not from the pertuzumab 
group. However, these analyses support the re-
sults of the intention-to-treat analysis.
Second, although the subgroups were pre-
defined, the analyses were exploratory and not 
powered for a statistical result. Small numbers of 
patients and data with wide confidence intervals 
limited interpretation of data among patients in 
the subgroup with nonvisceral disease, for ex-
ample. The hazard ratio for progression-free 
survival in this subgroup was 0.96 in the pri-
mary analysis,4 with an updated hazard ratio of 
0.83. A relatively small proportion of patients in 
this subgroup died (58 of 178 patients [32.6%] 
overall), and survival was long, with a median 
that was not reached in the pertuzumab group 
and that was 61.5 months in the control group 
(data not shown). This study included a large 
proportion of patients with visceral disease. The 
subgroup of patients who received adjuvant or 
neoadjuvant trastuzumab was also small, proba-
bly because trastuzumab was not widely available 
for this indication during the recruitment for 
this trial. However, the hazard ratios for progres-
sion-free and overall survival were similar (0.75 
and 0.80, respectively), suggesting a treatment 
benefit in favor of pertuzumab. One retrospec-
tive study has shown better outcomes with 
trastuzumab in patients with metastatic breast 
cancer who had received no previous adjuvant or 
neoadjuvant therapy with the drug,25 whereas a 
controlled cohort study showed no difference.26 
Further research is therefore needed.
In conclusion, in patients with HER2-positive 
metastatic breast cancer, the addition of pertuz-
umab to trastuzumab and docetaxel, as com-
pared with the addition of placebo, significantly 
increased the median overall survival to 56.5 
months, an improvement of 15.7 months over 
survival in the control group, and extended the 
results of previous analyses showing the efficacy 
of this drug combination.
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